BioMarin completes acquisition of Inozyme for $4.00 per share; Inozyme to delist

Inozyme Pharma, Inc.

BioMarin completed tender offer acquiring 69.8% of Inozyme shares at $4.00/share cash; subsequent merger completed July 1, 2025.
Inozyme will delist from Nasdaq and deregister under Exchange Act; Form 15 to be filed.
All Inozyme directors resigned; G. Eric Davis, Eric Fleekop, Brian Mueller appointed to board.
Executive officers resigned; G. Eric Davis became President, Eric Fleekop became Secretary.
In-the-money stock options and RSUs accelerated and cashed out at $4.00/share.

item 1.02item 2.01item 3.01item 3.03item 5.01item 5.03item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.